Biglycan (BGN) mRNA (BGN mRNA)

Biglycan (BGN) is a key component of the extracellular matrix belonging to the small leucine-rich proteoglycan (SLRP) family, consisting of a core protein with leucine-rich repeats and two glycosaminoglycan chains [1]. It functions as a structural organizer by binding to collagen types I, II, and VI, and as a signaling molecule that interacts with Toll-like receptors (TLR2/4) and the TGF-beta pathway [2]. In Duchenne muscular dystrophy, biglycan is essential for recruiting and stabilizing the dystrophin-associated protein complex, including utrophin, to the muscle cell membrane [3]. Conversely, in cancer and chronic inflammatory diseases, BGN mRNA is often overexpressed, acting as a damage-associated molecular pattern (DAMP) that promotes tumor progression and fibrosis [4]. Therapeutic approaches include the use of recombinant biglycan (e.g., TVN-102) for protein replacement therapy in muscular dystrophies [3]. Additionally, experimental RNA interference (siRNA) or antisense oligonucleotides (ASOs) are being explored to downregulate BGN mRNA in oncogenic or fibrotic contexts [5]. The dual role of biglycan as both a structural protein and a signaling molecule makes it a complex but promising target for various therapeutic indications [2, 4].

Other names

BiglycanBGNSLRP1BDSPG1PG-S1Bone/cartilage proteoglycan I

The primary mechanism of action for drugs targeting the biglycan pathway involves either the administration of recombinant biglycan protein to compensate for its deficiency and stabilize the muscle cell membrane in muscular dystrophies, or the use of RNA-targeting agents like siRNA and antisense oligonucleotides to reduce BGN mRNA levels in cancer and fibrotic diseases, thereby inhibiting pro-tumorigenic and pro-fibrotic signaling [3, 4, 5].